GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » PB Ratio

IVERIC bio (IVERIC bio) PB Ratio : 11.49 (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), IVERIC bio's share price is $39.95. IVERIC bio's Book Value per Share for the quarter that ended in Mar. 2023 was $3.48. Hence, IVERIC bio's PB Ratio of today is 11.49.

The historical rank and industry rank for IVERIC bio's PB Ratio or its related term are showing as below:

ISEE' s PB Ratio Range Over the Past 10 Years
Min: 1.86   Med: 13.39   Max: 157.45
Current: 11.49

During the past 12 years, IVERIC bio's highest PB Ratio was 157.45. The lowest was 1.86. And the median was 13.39.

ISEE's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.385 vs ISEE: 11.49

During the past 12 months, IVERIC bio's average Book Value Per Share Growth Rate was 21.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 18.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 20.70% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of IVERIC bio was 26.40% per year. The lowest was -34.70% per year. And the median was 18.30% per year.

Back to Basics: PB Ratio


IVERIC bio PB Ratio Historical Data

The historical data trend for IVERIC bio's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio PB Ratio Chart

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 3.63 3.25 5.35 5.47

IVERIC bio Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.86 3.84 8.34 5.47 7.00

Competitive Comparison of IVERIC bio's PB Ratio

For the Biotechnology subindustry, IVERIC bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVERIC bio's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's PB Ratio distribution charts can be found below:

* The bar in red indicates where IVERIC bio's PB Ratio falls into.



IVERIC bio PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

IVERIC bio's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2023)
=39.95/3.476
=11.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


IVERIC bio  (NAS:ISEE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


IVERIC bio PB Ratio Related Terms

Thank you for viewing the detailed overview of IVERIC bio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IVERIC bio (IVERIC bio) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
Keith Westby officer: SVP & COO ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll officer: SVP, CFO and Treasurer ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms officer: Senior Vice President, CCO FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney officer: EVP, Chief Business Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller director 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel officer: EVP, Chief Strategy & Business C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer director, officer: Chief Executive Officer ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142

IVERIC bio (IVERIC bio) Headlines